Loading
A phase 2 trial of Fulvestrant and Tinengotinib in HR-positive / HER2-negative breast cancer, run by TransThera Sciences (Nanjing), Inc., now recruiting.
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment is a phase 2 interventional study registered as NCT07498478 by TransThera Sciences (Nanjing), Inc., with 94 participants planned, started 2026-03-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tinengotinib at the optimal dose combined with Fulvestrant, Tinengotinib and tinengotinib combined with fulvestrant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TransThera Sciences, Tinengotinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/